A study on biorelevant calciprotein particles: Effect of stabilizing agents on the formation and crystallization mechanisms

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Calciprotein particles (CPPs) are endogenous nanoparticles consisting of hybrid mineral-organic colloidal complexes made of calcium phosphates and Fetuin-A (Fet-A), a protein that in physiological conditions binds to amorphous calcium phosphate forming primary CPP (CPP1). CPP1 can crystallize resulting in hydroxyapatite-based secondary CPP (CPP2) that can eventually precipitate leading to vascular calcifications. The treatment of patients with molecules and ions that delay the amorphous-to-crystalline transition has shown promising results from a clinical perspective, but the study of their mechanism of action has not been thoroughly examined so far.

Related collections

Most cited references 54

Record: found
Abstract: not found
Article: not found

Analysis of Macromolecular Polydispersity in Intensity Correlation Spectroscopy: The Method of Cumulants

Dennis Koppel (1972)

0 comments Cited 311 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.

Cora Schäfer, Alexander Heiss, Anke Schwarz … (2003)

Ectopic calcification is a frequent complication of many degenerative diseases. Here we identify the serum protein alpha2-Heremans-Schmid glycoprotein (Ahsg, also known as fetuin-A) as an important inhibitor of ectopic calcification acting on the systemic level. Ahsg-deficient mice are phenotypically normal, but develop severe calcification of various organs on a mineral and vitamin D-rich diet and on a normal diet when the deficiency is combined with a DBA/2 genetic background. This phenotype is not associated with apparent changes in calcium and phosphate homeostasis, but with a decreased inhibitory activity of the Ahsg-deficient extracellular fluid on mineral formation. The same underlying principle may contribute to many calcifying disorders including calciphylaxis, a syndrome of severe systemic calcification in patients with chronic renal failure. Taken together, our data demonstrate a critical role of Ahsg as an inhibitor of unwanted mineralization and provide a novel therapeutic concept to prevent ectopic calcification accompanying various diseases.